Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Non-metastatic NSCLC and other thoracic malignancies

2337 - Patient-reported outcomes (PROs) and impact of lactate dehydrogenase (LDH) levels on outcomes in a phase 3 trial (NGR015) with best investigator choice (BIC) plus or minus NGR-hTNF in previously treated patients with malignant pleural mesothelioma (MPM)


10 Oct 2016


Non-metastatic NSCLC and other thoracic malignancies


Vanesa Gregorc


Annals of Oncology (2016) 27 (6): 522-525. 10.1093/annonc/mdw391


V. Gregorc1, A. Bulotta1, M.G. Viganò1, G. Citterio1, G. Petrella1, E. Brioschi1, M. Ducceschi1, L. Gianni1, S. Colombi2, G. Rossoni2, G. Salini2, V. Savia2, A. Lambiase2, C. Bordignon2

Author affiliations

  • 1 Department Of Oncology, San Raffaele Scientific Institute, 20133 - Milano/IT
  • 2 Clinical Development, MolMed, 20133 - Milan/IT


Abstract 2337


NGR-hTNF selectively binds to CD13-expressing blood vessels. CD13 is upregulated by tumor hypoxia/angiogenesis, which are associated with high LDH serum levels. Patients (pts) failing a 1st-line pemetrexed-based regimen were randomized in NGR015 trial to weekly NGR-hTNF (N; n = 200) or placebo (P; n = 200) both given with BIC, including gemcitabine, vinorelbine or doxorubicin (95% of pts) or supportive care (5%).


PROs were assessed with the MPM-LCSS questionnaire, based on a 100-mm visual analog scale (with 0 as best rating) for 5 major symptoms (appetite loss, fatigue, cough, dyspnea and pain) and 3 summary items (total distress, activity and quality of life [QoL]). PROs measures were time to symptomatic deterioration (TSD; ≥ 25% increase) and responder analysis (≥ 10% decrease). We explored also the predictivity of baseline LDH (median 274 U/L; IQR 196 to 388) for N benefit.


At baseline, PROs completion rate (88% vs 92%) and scores (median 36 vs 36) were balanced between N and P arms, respectively. Scores inversely correlated with OS (p 


NGR-hTNF has improved OS in MPM pts rapidly progressing after front-line therapy, without altering QoL and with increasing effects noted with increasing LDH levels.

Clinical trial identification


Legal entity responsible for the study





S. Colombi, G. Rossoni, G. Salini, V. Savia, A. Lambiase, C. Bordignon: Employee of MolMed.

All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings